Belatacept is a medication used to help prevent the body from rejecting a transplanted kidney. It works by weakening the immune system so that it does not attack the new kidney. In this trial, belatacept is being tested to see if it can be a better option for young people who have had a kidney transplant, compared to other medications they might be taking.

Calcineurin Inhibitors are a group of medications that are commonly used to prevent organ rejection in people who have received a transplant. They work by suppressing the immune system to stop it from attacking the transplanted organ. In this study, the effects of continuing with calcineurin inhibitors are being compared to switching to belatacept to see which is more effective for young kidney transplant recipients.

Adolescent Renal Allografts – Adolescent renal allografts refer to kidney transplants received by individuals in their teenage years. After transplantation, the body may recognize the new kidney as foreign, potentially leading to immune responses. Over time, the transplanted kidney may experience changes in function, which can be monitored through measures like estimated glomerular filtration rate (eGFR). The progression of the condition involves maintaining the health and function of the transplanted kidney while managing the body’s immune response. The focus is on ensuring the kidney continues to function properly and supports the body’s needs. Regular monitoring and adjustments in care are essential to support the long-term health of the transplant.